BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 16782636)

  • 1. Chemoprevention for colon cancer: new opportunities, fact or fiction?
    Terhaar Sive Droste JS; Tuynman JB; Van Dullemen HM; Mulder CJ
    Scand J Gastroenterol Suppl; 2006; (243):158-64. PubMed ID: 16782636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease.
    Chan EP; Lichtenstein GR
    Gastroenterol Clin North Am; 2006 Sep; 35(3):675-712. PubMed ID: 16952746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammatory bowel disease as a risk factor for colorectal cancer.
    Lukas M
    Dig Dis; 2010; 28(4-5):619-24. PubMed ID: 21088413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colorectal cancer prevention: is an ounce of prevention worth a pound of cure?
    Gill S; Sinicrope FA
    Semin Oncol; 2005 Feb; 32(1):24-34. PubMed ID: 15726503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoprevention of colorectal cancer: feasibility in everyday practice?
    Herszényi L; Farinati F; Miheller P; Tulassay Z
    Eur J Cancer Prev; 2008 Nov; 17(6):502-14. PubMed ID: 18941372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis.
    Vera A; Gunson BK; Ussatoff V; Nightingale P; Candinas D; Radley S; Mayer A; Buckels JA; McMaster P; Neuberger J; Mirza DF
    Transplantation; 2003 Jun; 75(12):1983-8. PubMed ID: 12829898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease.
    Brackmann S; Andersen SN; Aamodt G; Langmark F; Clausen OP; Aadland E; Fausa O; Rydning A; Vatn MH
    Scand J Gastroenterol; 2009; 44(1):46-55. PubMed ID: 18609187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colon cancer in inflammatory bowel disease: recent trends, questions and answers.
    Viennot S; Deleporte A; Moussata D; Nancey S; Flourié B; Reimund JM
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S190-201. PubMed ID: 20117342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspirin and other nonsteroidal anti-inflammatory agents in the prevention of colorectal cancer.
    Sandler RS
    Important Adv Oncol; 1996; ():123-37. PubMed ID: 8791132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoprevention of colorectal cancer in inflammatory bowel disease? A potential role for folate.
    Mouzas IA; Papavassiliou E; Koutroubakis I
    Ital J Gastroenterol Hepatol; 1998 Aug; 30(4):421-5. PubMed ID: 9789142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoprophylaxis in gastrointestinal tumors.
    Zilli M; Iacobelli S
    Eur Rev Med Pharmacol Sci; 2010 Apr; 14(4):285-91. PubMed ID: 20496537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study.
    Bernstein CN; Nugent Z; Blanchard JF
    Am J Gastroenterol; 2011 Apr; 106(4):731-6. PubMed ID: 21407180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoprevention of colorectal cancer.
    Das D; Arber N; Jankowski JA
    Digestion; 2007; 76(1):51-67. PubMed ID: 17947819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic inflammatory bowel disease and cancer.
    Pohl C; Hombach A; Kruis W
    Hepatogastroenterology; 2000; 47(31):57-70. PubMed ID: 10690586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males.
    Söderlund S; Granath F; Broström O; Karlén P; Löfberg R; Ekbom A; Askling J
    Gastroenterology; 2010 May; 138(5):1697-703. PubMed ID: 20167217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Risk factors for ulcerative colitis associated colorectal cancers in a Hungarian cohort of ulcerative colitis patients].
    Lakatos L; Mester G; Erdélyi Z; David G; Pandúr T; Balogh M; Fischer S; Vargha P; Lakatos PL
    Orv Hetil; 2006 Jan; 147(4):175-81. PubMed ID: 16515026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carcinogenesis in inflammatory bowel disease.
    Herszenyi L; Miheller P; Tulassay Z
    Dig Dis; 2007; 25(3):267-9. PubMed ID: 17827953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoprevention of colorectal cancer: systematic review and economic evaluation.
    Cooper K; Squires H; Carroll C; Papaioannou D; Booth A; Logan RF; Maguire C; Hind D; Tappenden P
    Health Technol Assess; 2010 Jun; 14(32):1-206. PubMed ID: 20594533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surveillance strategies in inflammatory bowel disease.
    Schmidt C; Bielecki C; Felber J; Stallmach A
    Minerva Gastroenterol Dietol; 2010 Jun; 56(2):189-201. PubMed ID: 20485256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An introduction to aspirin, NSAids, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part II.
    Moyad MA
    Semin Urol Oncol; 2001 Nov; 19(4):306-16. PubMed ID: 11769882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.